Possible Role of Adipose Tissue and the Endocannabinoid System in Coronavirus Disease 2019 Pathogenesis: Can Rimonabant Return?

This is the main conclusion of a recent study describing a strong relationship between the degree of obesity and the severity of COVID-19 infection. Obesity has various negative consequences relative to the course of COVID-19, including adverse effects on lung physiology, and induces comorbidities such as type II diabetes or hypertension. However, additional mechanisms involving the low-grade inflammatory state accompanying obesity can also be suggested.

[1]  F. Crea,et al.  COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options , 2020, Cardiovascular research.

[2]  D. Cota,et al.  Anti-obesity therapy with peripheral CB1 blockers: from promise to safe(?) practice , 2020, International Journal of Obesity.

[3]  J. Kohn,et al.  Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms , 2020, Brain, Behavior, and Immunity.

[4]  D. Mathieu,et al.  High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) Requiring Invasive Mechanical Ventilation , 2020, Obesity.

[5]  Xiaohui Cui,et al.  The Effects of Obesity on Outcome in Preclinical Animal Models of Infection and Sepsis: A Systematic Review and Meta-Analysis , 2019, Journal of obesity.

[6]  A. Zampronio,et al.  Cannabinoid CB1 Receptor Antagonist Rimonabant Decreases Levels of Markers of Organ Dysfunction and Alters Vascular Reactivity in Aortic Vessels in Late Sepsis in Rats , 2019, Inflammation.

[7]  M. Nagarkatti,et al.  Role of microRNA in CB1 antagonist–mediated regulation of adipose tissue macrophage polarization and chemotaxis during diet-induced obesity , 2019, The Journal of Biological Chemistry.

[8]  F. Rezaei,et al.  The Role of Cannabinoid Receptor 1 in the Immunopathology of Respiratory Syncytial Virus. , 2018, Viral immunology.

[9]  María Méndez-Lago,et al.  Adipocyte cannabinoid receptor CB1 regulates energy homeostasis and alternatively activated macrophages , 2017, The Journal of clinical investigation.

[10]  M. R. Iyer,et al.  Cannabinoid CB1 receptor overactivity contributes to the pathogenesis of idiopathic pulmonary fibrosis. , 2017, JCI insight.

[11]  P. Neumann,et al.  The intracerebroventricular injection of rimonabant inhibits systemic lipopolysaccharide-induced lung inflammation , 2015, Journal of Neuroimmunology.

[12]  C. Silvestri,et al.  The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. , 2013, Cell metabolism.

[13]  K. Fujioka,et al.  A one‐year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes , 2010, Diabetes, obesity & metabolism.

[14]  J. Després,et al.  Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. , 2005, The New England journal of medicine.

[15]  Jean-Daniel Zucker,et al.  Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. , 2005, Diabetes.